Sign Out
CellCept is indicated for the prophylaxis of acute organ rejection and for the treatment of first or refractory organ rejection in patients receiving allogeneic renal transplants.
CellCept is indicated for the prophylaxis of acute organ rejection in patients receiving allogeneic cardiac transplants. (In the treated population, MMF improved survival in the first year after transplantation).
CellCept is indicated for the prophylaxis of acute organ rejection in patients receiving allogeneic hepatic transplants.
CellCept should be used concomitantly with ciclosporin and corticosteroids.
CellCept is indicated for induction and maintenance therapy of patients with Class III-IV lupus nephritis (diagnosed according to International Society of Nephrology/Renal Pathology Society classification).
